Neuphoria Therapeutics (NEUP) Free Cash Flow (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Free Cash Flow of -$3.4 million for Q1 2026, down 129.69% year-over-year from $11.5 million in Q1 2025, and up 46.92% on a QoQ basis from -$6.4 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Free Cash Flow data on file, last reported at -$3.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 129.69% year-over-year to -$3.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.2 million (down 2734.23% YoY) and the FY2025 annual result came in at $100000.0, up 100.68% from the prior year.
- Free Cash Flow improved to -$3.4 million in Q1 2026 per NEUP's latest filing, from -$6.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $11.5 million in Q1 2025 and bottomed at -$6.4 million in Q4 2025.
- The 4-year median for Free Cash Flow is -$3.6 million (2025), against an average of -$2.6 million.
- The widest annual swing landed in 2025, when Free Cash Flow soared 447.59%; it then sank 129.69% in 2026.
- Tracing NEUP's Free Cash Flow over 4 years: stood at -$3.9 million in 2023, then grew by 14.88% to -$3.4 million in 2024, then slumped by 90.74% to -$6.4 million in 2025, then surged by 46.92% to -$3.4 million in 2026.
- Per Business Quant, the three latest NEUP Free Cash Flow figures stand at -$3.4 million (Q1 2026), -$6.4 million (Q4 2025), and -$3.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | -3.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -6.44 Mn |
| Dec 31, 2025 | -6.44 Mn |
| Sep 30, 2025 | -3.79 Mn |
| Sep 30, 2025 | -3.79 Mn |
| Jun 30, 2025 | -3.59 Mn |
| Jun 30, 2025 | -3.59 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | -3.36 Mn |
| Dec 31, 2024 | -3.36 Mn |
| Sep 30, 2024 | -4.43 Mn |
| Sep 30, 2024 | -4.43 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -3.30 Mn |
| Mar 31, 2024 | -3.30 Mn |
| Dec 31, 2023 | -3.95 Mn |
| Dec 31, 2023 | -3.95 Mn |
| Sep 30, 2023 | -4.43 Mn |
| Sep 30, 2023 | -4.43 Mn |